Icer Vascepa Xarelto Costeffective In Cvd Prevention | Latest News RSS feed

Icer Vascepa Xarelto Costeffective In Cvd Prevention - Latest News


ICER: Vascepa, Xarelto Cost-Effective in CVD Prevention

Rivaroxaban (Xarelto) added to aspirin and icosapent ethyl (Vascepa) added to standard prevention therapies are of at least modest net clinical benefit and cost-effective, according to a preliminary ... read more

Add your link right here

Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page. read more

Amarin Reports Second Quarter 2019 Financial Results and Operational Update

Search MarketWatch Home Latest News Watchlist Markets U.S. Markets Canada Europe & Middle East Asia Emerging Markets Latin America Market Data ... read more

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

In final guidance published today (25 July), NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare ... contraceptive therapy and the presence of co-morbidities such as heart disease. It is ... read more

Looking for another news?


Amarin Reports Second Quarter 2019 Financial Results and Operational Update

Increased cash balance to ensure robust launch of Vascepa ... CVD leads to one in every three deaths – one death approximately every 38 seconds – with annual treatment cost in excess of $500 billion. read more


Brilinta for Prevention in T2D; Pacer Recall; PCSK9 for Statin Myopathy Cases

ICER also announced plans to look at icosapent ethyl (Vascepa) and rivaroxaban (Xarelto) as add-on therapies in cardiovascular disease. Medicare Advantage plans may be driving up quality of care in ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us